The global demand for Viral Vector Production Market is presumed to reach the market size of nearly USD 27.89 BN by 2030 from USD 17.9 BN in 2022 with a CAGR of 5.7% under the study period 2023 - 2030.
Viral vector production refers to the process of generating and manufacturing viral vectors, which are vehicles used to deliver genetic material into cells for various purposes, including gene therapy, vaccine development, and research. Viral vectors are modified viruses that are designed to carry therapeutic genes, vaccine antigens, or other genetic material into target cells, facilitating the expression of desired proteins or the correction of genetic defects.
The Viral vector production market is experiencing significant growth driven by key factors in the biotechnology and healthcare landscape. The rise in gene therapy research, fueled by advancements in biotechnology and gene editing technologies, propels the demand for viral vectors as essential tools for delivering therapeutic genes. The expansion of cell and gene therapy clinical trials, particularly in the context of CAR-T cell therapies for cancer treatment, contributes to the market's momentum. Increased funding and investments in gene therapy and biotechnology, along with the growing incidence of genetic disorders, underline the importance of viral vectors in developing targeted therapeutic solutions. Technological innovations in vector design, a surge in viral vector-based vaccines, and a global focus on addressing rare diseases further fuel market expansion. Regulatory support and approvals play a crucial role in fostering a conducive environment for investments and the development of viral vectors for clinical applications. The market's trajectory reflects the integral role of viral vectors in advancing gene therapies, vaccines, and biotechnological innovations.
The research report covers Porter’s Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry’s structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of viral vector production. The growth and trends of viral vector production industry provide a holistic approach to this study.
This section of the viral vector production market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Vector Type
By Disease
By Application
By Mode
By End-User
This section covers the regional outlook, which accentuates current and future demand for the Viral Vector Production market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Viral Vector Production market include Pfizer, Inc., Johnson & Johnson, AstraZeneca, Sanofi, Novartis AG, Spark Therapeutics, Inc. (F. Hoffmann-La Roche Ltd.), GlaxoSmithKline plc, Merck KGaA (Merck & Co., Inc.), Lonza, FUJIFILM Diosynth Biotechnologies, Inc., Oxford Biomedica plc, Amgen, Inc., Ferring B.V., UniQure N.V., bluebird bio, Inc., GenScript ProBio, Thermo Fisher Scientific, Inc., Gamaleya Research Institute Industries. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
1 . PREFACE
1.1. Report Description
1.1.1. Objective
1.1.2. Target Audience
1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
1.3.1. Market Research Process
1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
2.1. Highlights of Market
2.2. Global Market Snapshot
3 . VIRAL VECTOR PRODUCTION – INDUSTRY ANALYSIS
3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter’s Five Force Analysis
3.7. Market Attractiveness Analysis
3.7.1 Market Attractiveness Analysis By Vector Type
3.7.2 Market Attractiveness Analysis By Disease
3.7.3 Market Attractiveness Analysis By Application
3.7.4 Market Attractiveness Analysis By Mode
3.7.5 Market Attractiveness Analysis By End-User
3.7.6 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1. List of Raw Materials
4.2.2. Raw Material Manufactures List
4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1. Direct Marketing
4.4.2. Indirect Marketing
4.4.3. Marketing Channel Development Trend
5 . GLOBAL VIRAL VECTOR PRODUCTION MARKET ANALYSIS BY VECTOR TYPE
5.1 Overview by Vector Type
5.2 Historical and Forecast Data
5.3 Analysis by Vector Type
5.4 Adenovirus Historic and Forecast Sales by Regions
5.5 Adeno-Associated Virus Historic and Forecast Sales by Regions
5.6 Retroviruses Historic and Forecast Sales by Regions
5.7 Others (Baculoviruses, Lentivirus, Etc.) Historic and Forecast Sales by Regions
6 . GLOBAL VIRAL VECTOR PRODUCTION MARKET ANALYSIS BY DISEASE
6.1 Overview by Disease
6.2 Historical and Forecast Data
6.3 Analysis by ...